Fruzaqla Fruquintinib Refractory Colorectal Cancer Clinical Guide 2026
Author: Critical Kare PharmaColorectal Oncology Desk
On November 6, 2026, gastrointestinal oncology guidelines solidified Fruzaqla® (Fruquintinib 1 mg and 5 mg capsules) by HUTCHMED and Takeda as the preferred oral targeted therapy for heavily pretreated metastatic colorectal cancer (mCRC).
Following landmark international validation in the Phase 3 FRESCO-2 clinical trial, Fruzaqla addresses a critical unmet need for patients who have progressed through fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, anti-VEGF therapy, and (if RAS wild-type) anti-EGFR therapy.
Through Critical Kare Pharma, original manufacturer supplies of Fruzaqla Fruquintinib Capsules are supplied globally under certified pharmaceutical distribution standards.
Unprecedented Kinase Selectivity: VEGFR-1, -2, and -3
Unlike earlier multi-kinase inhibitors (such as regorafenib) that non-specifically inhibit KIT, RET, RAF, and PDGFR, fruquintinib was designed with potent selectivity solely for VEGFR-1, VEGFR-2, and VEGFR-3 kinase domains:
- Nanomolar IC50: Inhibits VEGFR-2 phosphorylation at 25 nM, completely cutting off tumor neovascularization and endothelial proliferation.
- Minimized Off-Target Toxicity: Sparing non-VEGFR kinases significantly reduces the severe hand-foot skin reactions, fatigue, and transaminitis that frequently cause treatment termination with non-selective agents.
The FRESCO-2 Trial Evidence
Conducted across 124 hospitals in North America, Europe, and Asia-Pacific:
- Overall Survival: Fruquintinib reduced the risk of death by 34% compared to placebo (median OS 7.4 vs 4.8 months; HR 0.66, p < 0.001).
- Progression-Free Survival: Tripled median PFS (3.7 vs 1.8 months; HR 0.32, p < 0.001), demonstrating consistent disease control irrespective of prior regorafenib or TAS-102 therapy.
Dosing Schedule & Sourcing Pathways
Dosage is 5 mg orally once daily for 21 consecutive days followed by 7 days off (28-day cycle). Routine blood pressure monitoring is essential. Critical Kare Pharma arranges rapid dispatch with complete analytical release testing directly to oncology dispensaries worldwide.
